ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory ...

If you are wondering whether ImmunityBio's recent run makes the stock look expensive or still interesting on price, this article will walk through what the numbers say about its current value. The ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

Financial giants have made a conspicuous bullish move on ImmunityBio. Our analysis of options history for ImmunityBio (NASDAQ:IBRX) revealed 19 unusual trades. Delving into the details, we found 57% ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them. ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation ...

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver City-based ImmunityBio Inc. announced that the European Medicines Agency, ...

ImmunityBio Inc. (NASDAQ: IBRX) shares are up during Tuesday’s premarket session as the company is reportedly advancing its regulatory efforts. This positive movement follows the announcement of ...